Literature DB >> 12408471

Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer.

D Nikolic-Vukosavljevic1, K Kanjer, Z Neskovic-Konstantinovic, D Vukotic.   

Abstract

The biological significance of estrogen receptor-negative but progesterone receptor-positive breast carcinomas is not clear. In the present study the aggressiveness of breast carcinomas in relation to ER and PgR status has been investigated. The probability of disease-free survival in 297 node-negative breast carcinoma patients was monitored during a follow-up ranging from six to 96 months (median 45 months). Steroid hormone receptor content was assayed with the biochemical method recommended by the EORTC. The probability of disease-free survival was significantly worse for patients with ER-negative, PgR-positive carcinomas compared to the other three steroid hormone receptor phenotypes. Our results suggest that ER-negative, PgR-positive breast carcinomas are biologically different in terms of aggressiveness from the other steroid hormone receptor phenotypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408471     DOI: 10.1177/172460080201700309

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  3 in total

1.  Epimorphin is a novel regulator of the progesterone receptor isoform-a.

Authors:  Jamie L Bascom; Derek C Radisky; Eileen Koh; Jimmie E Fata; Alvin Lo; Hidetoshi Mori; Neda Roosta; Yohei Hirai; Mina J Bissell
Journal:  Cancer Res       Date:  2013-07-18       Impact factor: 12.701

2.  Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Authors:  Ke-da Yu; Gen-hong Di; Jiong Wu; Jin-song Lu; Kun-wei Shen; Guang-yu Liu; Zhen-zhou Shen; Zhio-ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-17       Impact factor: 4.553

3.  Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients.

Authors:  Li-Heng Yang; Hsin-Shun Tseng; Che Lin; Li-Sheng Chen; Shou-Tung Chen; Shou-Jen Kuo; Dar-Ren Chen
Journal:  J Breast Cancer       Date:  2012-09-28       Impact factor: 3.588

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.